About this trial
This study aims to observe inflammatory biomarkers and their trend over the history of the disease in patients suffering from MPN Ph negative; it also wants to identify any correlations between the aforementioned biomarkers and disease outcomes, considering first of all the occurrence of thrombo-haemorrhagic events and the evolution in the accelerated / blast phase of the disease, shedding light on new tools that can potentially guarantee a prompt and better risk stratification
Eligibility criteria
Qualifiers
Age ≥ 18 years at the time of diagnosis of MPN Ph negative
Diagnosis of PV, ET, PMF or post PV and post ET MF, according to current WHO or IWG-MRT criteria (diagnosis since 2000)
Obtaining informed consent
Disqualifiers
Life expectancy of less than 6 months
Accelerated phase myelofibrosis or MPN with signs of leukemic evolution
Trial design
Treatments tested in this trial
- Not listed